首页> 美国卫生研究院文献>Environmental Health and Toxicology >Ginkgo biloba extract (EGb761) did not express estrogenic activity in an immature rat uterotrophic assay
【2h】

Ginkgo biloba extract (EGb761) did not express estrogenic activity in an immature rat uterotrophic assay

机译:银杏叶提取物(EGb761)在未成熟的大鼠子宫营养试验中未表达雌激素活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ginkgo biloba is a dioecious tree that has been used in traditional Chinese medicine for about 5,000 years. In previous studies on Ginkgo biloba extract (EGb761) using in vitro systems, we confirmed that EGb761 has biphasic effects on estrogenicity. In this study, we evaluated the agonistic and antagonistic activities of EGb761 using a uterotrophic assay in immature female rats. To evaluate agonistic and antagonistic effects of EGb761 on uterus, 21-day-old immature Sprague-Dawley (SD) female rats were treated with EGb761 (100, 200, or 400 mg/kg) by oral gavage, 10 μg/kg of estradiol (E2) or 1 mg/kg tamoxifen (TM) by subcutaneous injection, or with EGb761 plus E2 or TM for 3 consecutive days. At the end of the treatment period, animals were sacrificed and their body weights and organ weights (liver, lung, spleen and kidney) were measured. In addition, estrogen-related gene expressions (IGFBP-1 in liver and CaBP-9 in uterus) were determined. During the experiment, no animal showed clinical signs, a change in body weight or died. EGb761 treatment alone had no effect on absolute/relative uterine weight, luminal epithelial cell height (LECH, μm), or luminal circumference (LC, μm). In addition, uterine weights, LECHs, and LC induced by E2 or TM were not significantly changed by EGb761 at any dose. These results collectively suggested EGb761 has no agonistic/antagonistic effects in utero.
机译:银杏是一棵雌雄异异的树,已经在中药中使用了大约5,000年。在先前使用体外系统对银杏叶提取物(EGb761)进行的研究中,我们证实了EGb761对雌激素具有双相作用。在这项研究中,我们使用未成熟雌性大鼠的子宫营养评估了EGb761的激动和拮抗活性。为了评估EGb761对子宫的拮抗作用和拮抗作用,对21天大的未成熟Sprague-Dawley(SD)雌性大鼠进行口服灌胃,10μg/ kg雌二醇处理的EGb761(100、200或400 mg / kg) (E2)或1 mg / kg他莫昔芬(TM)皮下注射,或连续3天与EGb761加E2或TM配合使用。在治疗期结束时,处死动物并测量其体重和器官重量(肝,肺,脾和肾)。此外,确定了雌激素相关基因的表达(肝脏中的IGFBP-1和子宫中的CaBP-9)。在实验过程中,没有动物表现出临床体征,体重变化或死亡。单独进行EGb761治疗对绝对/相对子宫重量,腔上皮细胞高度(LECH,μm)或腔周长(LC,μm)没有影响。此外,EGb761在任何剂量下均未显着改变E2或TM诱导的子宫重量,LECH和LC。这些结果共同表明EGB761对子宫没有激动/拮抗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号